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BACKGROUND & AIMS: Host cell lipid rafts form a
scaffold required for replication of hepatitis C virus
(HCV). Serine palmitoyltransferases (SPTs) produce
sphingolipids, which are essential components of the
lipid rafts that associate with HCV nonstructural
proteins. Prevention of the de novo synthesis of sphin-
golipids by an SPT inhibitor disrupts the HCV replication
complex and thereby inhibits HCV replication. We
investigated the ability of the SPT inhibitor NA808
to prevent HCV replication in cells and mice.METHODS:
We tested the ability of NA808 to inhibit SPT’s
enzymatic activity in FLR3-1 replicon cells. We used a
replicon system to select for HCV variants that became
resistant to NA808 at concentrations 4- to 6-fold the
50% inhibitory concentration, after 14 rounds of cell
passage. We assessed the ability of NA808 or telaprevir
to inhibit replication of HCV genotypes 1a, 1b, 2a, 3a,
and 4a in mice with humanized livers (transplanted
with human hepatocytes). NA808 was injected intrave-
nously, with or without pegylated interferon alfa-2a and
HCV polymerase and/or protease inhibitors. RESULTS:
NA808 prevented HCV replication via noncompetitive
inhibition of SPT; no resistance mutations developed.
NA808 prevented replication of all HCV genotypes
tested in mice with humanized livers. Intravenous
NA808 signiﬁcantly reduced viral load in the mice
and had synergistic effects with pegylated interferon
alfa-2a and HCV polymerase and protease inhibitors.
CONCLUSIONS: The SPT inhibitor NA808 prevents
replication of HCV genotypes 1a, 1b, 2a, 3a, and 4a in
cultured hepatocytes and in mice with humanized
livers. It might be developed for treatment of HCV
infection or used in combination with pegylated
interferon alfa-2a or HCV polymerase or protease
inhibitors.
Keywords: Direct-Acting Antiviral Agents; DAAs; HCV
Lifecycle; Drug.epatitis C virus (HCV) is a major cause of morbidity,Haffecting approximately 170 million people world-
wide.1 In many cases, HCV results in a persistent infection
that evades the host immune response, leading to chronic
liver disease, chronic hepatitis, cirrhosis, and hepatocel-
lular carcinoma.2
The current therapy for chronic hepatitis C is a com-
bination of weekly injections of pegylated interferon alfa-
2a (PEG-IFN) and twice-daily oral doses of ribavirin (RBV).
Unfortunately, this combination therapy has limited efﬁ-
cacy and signiﬁcant side effects.3,4 Although the HCV
NS3/4A protease inhibitors telaprevir and SCH503034
(boceprevir) are approved for the treatment of chronic
HCV infection, these compounds must be combined with
the current standard of care to be efﬁcacious, and they
cannot cure all infected individuals, including IFN-
intolerant patients.57 Therefore, antiviral combinations
that can achieve superior sustained virologic response
without the use of IFN or RBV are needed.
IFN-free combinations of direct-acting antiviral agents
(DAAs) have been tested for clinical use as novel anti-HCV
therapies.810 Emerging data suggest that DAAs, including
NS3/4 serine protease inhibitors, NS5B RNA-dependent
RNA polymerase inhibitors, and NS5A inhibitors, when
used in combination, can achieve signiﬁcant antiviral ac-
tivity, but might select for resistance, which can become a
primary cause of treatment failure in clinical studies,
especially in difﬁcult-to-treat HCV genotypes.8,9 Addition-
ally, differences in HCV genotypes can result in reduced
antiviral activities of certain DAAs and DAA combina-
tions.11 Therefore, development of additional antiviral
agents with diverse resistance proﬁles and efﬁcacy against a
wide spectrum of HCV genotypes is necessary. Majorhttp://dx.doi.org/10.1053/j.gastro.2013.06.012
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combinations with a high barrier to resistance for the
treatment of HCV infection.
We identiﬁed a novel class of serine palmitoyltransferase
(SPT) inhibitors derived from fungal metabolites that
exhibited HCV replication-inhibiting activity.12 HCV
replication occurs on host cell lipid rafts that form a
scaffold for the HCV replication complex. Sphingolipids,
the downstream products of SPT action, are essential
components of lipid rafts associated with HCV non-
structural proteins on this microdomain. Prevention of
the de novo synthesis of sphingolipids by an SPT inhibitor
disrupts the HCV replication complex and thereby inhibits
HCV replication. This unique mechanism of host enzy-
metargeted viral inhibition was hypothesized to have
potential for a high barrier to resistance and for antiviral
activity across different HCV genotypes. We identiﬁed a
novel compound, NA808, which is a derivative of the
previously described compound NA255 with further
improved properties, including improved replicon potency
from a 50% effective concentration of 2 nM for NA255 to a
50% effective concentration of 0.84 nM for NA808.12
Here, we report the effectiveness of NA808 alone and in
combination with DAAs. We used chimeric mice with
humanized liver infected with HCV genotype 1a, 1b, 2a,
3a, and 4a to evaluate the potential of NA808 as a novel
host-targeted HCV inhibitor.Materials and Methods
Compounds
NA808 and telaprevir were synthesized by Chugai Phar-
maceutical Co., Ltd. (Tokyo, Japan). PEG-IFN was purchased
from Chugai Pharmaceutical Co., Ltd. Non-nucleoside poly-
merase inhibitor, HCV-796, and nucleoside polymerase inhibitor,
RO-9187,13 were synthesized by F. Hoffmann-La Roche Ltd.
(Basel, Switzerland).Development of Drug-Resistance Mutations in
HuH7 Cells Harboring Subgenomic Replicon
The HCV subgenomic replicon cell line R6 FLR-N14
(genotype 1b, HCV-N) was cultured with GlutaMax-I (DMEM-
GlutaMax-I; Invitrogen, Carlsbad, CA) containing 10% fetal bovine
serum in the presence of 0.5 mg/mL G418 and 4872 nMNA808
or 1.82.7 mM telaprevir at a concentration of 46 times the 50%
inhibitory concentration (IC50) value for 14 passages. For the
replicon assay, cells were seeded in 96-well tissue culture plates, and
a 3-fold gradual dilution of NA808 or telaprevir in 5% fetal bovine
serum supplemented GlutaMax-I was added. Serial dilutions of
both compoundswere prepared from the stock solutions dissolved
in dimethyl sulfoxide at a concentration of 1 mM for NA808 and
50 mM for telaprevir. Luciferase activity was determined with a
Steady-Glo luciferase assay kit (Promega, Madison, WI).Deep Sequencing of HCV Genomes From
Genotype 1b Replicon Cells and Genotype
1aLInfected Chimeric Mice
Deep sequencing of the HCV coding sequences was
performed by using the GS Junior System (Roche Diagnostics,Mannheim, Germany), according to manufacturer’s instructions.
First, the acid guanidinium thiocyanate-phenol-chloroform
extraction method was used to extract total RNA from the R6
FLR-N replicon cells after 14 passages with telaprevir or NA808
at a concentration of 6 times the IC50 value, or from the liver
tissue of HCV-infected chimeric mice that were treated with or
without NA808 for 14 days. Complementary DNA (cDNA) was
then synthesized from the total RNA with random primers by
using Superscript III Reverse Transcriptase (Invitrogen, Life
Technologies, Carlsbad, CA). The sequence of nucleotides
34299727 of the HCV genotype 1b replicon (R6NRz) genome
or nucleotides 3259381 of the HCV genotype 1a (HCG9)
genome, including all of the HCV protein coding sequence, was
divided into several segments of 1.53 kb with overlapping re-
gions. Four segments of the genotype 1b replicon genome were
ampliﬁed from the cDNA by polymerase chain reaction (PCR)
with speciﬁc primers (Supplementary Table 2), and 7 segments of
the genotype 1a (HCG9) genome were ampliﬁed from the cDNA
by nested PCR with the indicated primers (Supplementary
Table 3) by using PrimeSTAR GXL DNA Polymerase (TaKaRa
Bio, Shiga, Japan). The ampliﬁed segments of HCV cDNA were
puriﬁed from 1% agarose gels by using a MinElute Gel Extraction
Kit (Qiagen, Valencia, CA) and quantiﬁed by measuring absor-
bance at 260 nm with a NanoDrop 1000 Spectrophotometer
(Thermo Scientiﬁc, Wilmington, DE).
The cDNA segments covering the coding sequence of HCV
were then pooled together at approximately equimolar ratios.
The Covaris S220 system (Covaris, Woburn, MA) was used to
shear 500 ng of the pooled cDNA into 700- to 800-bp fragments.
The sheared cDNA fragments were puriﬁed with the MinElute
PCR Puriﬁcation Kit (Qiagen), ligated with RL MID adaptors
(Roche Diagnostics) to prepare the multiple cDNA libraries, and
further puriﬁed with Agencourt AMPure XP beads (Beckman
Coulter, Brea, CA). The quality and quantity of the libraries were
assessed by using an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA) and the KAPA Library Quantiﬁcation
Kit (Nippon Genetics, Tokyo, Japan), respectively. The libraries
were then subjected to emulsion PCR, and enriched DNA beads
(approximately 10% recovery) were loaded onto a picotiter plate
and pyrosequenced with a GS Junior sequencer by using tita-
nium chemistry (Roche Diagnostics). Several libraries derived
from the HCV genomes generated by different treatments were
sequenced in a single GS Junior run. The data obtained were
analyzed by the GS Reference Mapper software (Roche Di-
agnostics) to identify resistant mutations.SPT Assay
Crude extracts of the HCV subgenomic replicon cell line
FLR3-112 (genotype 1b, Con-1) were used as a source of SPT in
this assay. Brieﬂy, FLR3-1 cells were suspended in HSS buffer
(10 mM HEPES-KOH, 25 mM sucrose, and 0.1% sucrose mon-
olaurate) containing 1/100 volume of protease inhibitor cocktail
(Sigma, St Louis, MO) and sonicated 10 times with short pulses.
After centrifugation at 10,000 rpm for 10 minutes, the super-
natant was stored at 80C until use. Crude extract of FLR3-1
cells was added to 0.015 mL of a reaction mixture containing
200 mM HEPES buffer (pH 8.0), 5 mM EDTA, 10 mM dithio-
threitol, 0.05 mM pyridoxal 5-phosphate, 0.05 mM palmitoyl-
CoA, and 0.06 mM L-[14C]serine in the presence of NA808.
After a 15-minute incubation at 37C, 0.3 mL chloroform/
methanol (1:2, v/v), 0.1 mL phosphate-buffered saline, and
0.1 mL chloroform were added and mixed well. The extracts were
October 2013 ANTI-HCV ACTIVITY OF SPT INHIBITOR WITH DAAS 867spotted on TLC plates and chromatographed. Radioactive spots
were evaluated by using a Bio-imager.Infection of HCV Genotype 1a, 1b, 2a, 3a, and
4a in Chimeric Mice With Humanized Liver
Chimeric mice were purchased from PhoenixBio Co., Ltd.
(Hiroshima, Japan). The mice were generated by transplanting
human primary hepatocytes into severe combined immunodeﬁ-
cient mice carrying the urokinase plasminogen activator trans-
gene controlled by an albumin promoter (Alb-uPA). HCG9
(genotype 1a, GenBank accession number AB520610), HCR6
(genotype 1b, AY045702), HCR24 (genotype 2a, AY746460),
HCV-TYMM (genotype 3a, AB792683), and HCVgenotype4a/KM
(genotype 4a, AB795432) were intravenously injected into the
chimeric mice with humanized liver at 104 (for HCR6, HCR24,
HCV-TYMM, and HCVgenotype4a/KM) or 106 (for HCR6 and
HCG9) copies/mouse. After 4 weeks, the HCV RNA levels in the
mice sera had reached approximately 108 copies/mL for HCG9
and HCV-TYMM and approximately 107 copies/mL for HCR6,
HCR24, and HCVgenotype4a/KM. The protocols for animal ex-
periments were approved by our institutional ethics committee.
The animals received humane care according to National In-
stitutes of Health guidelines. Patients gave written informed
consent before collection of blood or tissue samples.Administration of NA808 and/or PEG-IFN,
Telaprevir, HCV-796, RO-9187 into HCV-
Infected Chimeric Mice With Humanized LiverD N
A
LTreatment was started 12 weeks after HCV inoculation
and continued for 14 days. Each treatment group contained at
least 3 animals. NA808, PEG-IFN, RO-9187, HCV-796, and
telaprevir were administered alone or in combination to chimeric
mice infected with HCV genotype 1a (HCG9), genotype 1b
(HCR6), genotype 2a (HCR24), genotype 3a (HCV-TYMM), or
genotype 4a (HCVgenotype4a/KM). Blood samples and liver
samples were collected according to the protocols shown in
Supplementary Table 1. All DAAs were used at suboptimal doses
to allow the demonstration of synergy when administered in
combination therapy.B
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Reverse Transcription PCRTRTotal RNA was puriﬁed from 1 mL chimeric mouse
serum by using SepaGene RV-R (Sanko Junyaku Co., Ltd.,
Tokyo, Japan) and total RNA was prepared from liver tissue by
the acid guanidinium thiocyanate-phenol-chloroform extraction
method. HCV RNA was quantiﬁed by quantitative real-time PCR
using techniques reported previously.15 This technique has a
lower limit of detection of approximately 4000 copies/mL for
serum. Therefore, all samples in which HCV RNA was unde-
tectable were assigned this minimum value.Statistical Analysis
Statistical analysis was performed using the Student
t test. A P value <.05 was considered statistically signiﬁcant.Results
In Vitro Characteristics of NA808
NA808 (Figure 1A), a derivative of NA255 isolated
from fungal metabolites of Fusarium incarnatum F1476demonstrated potent antiviral activity in HCV genotype
1b replicon cells with no apparent cellular toxicity under
the assay conditions (Supplementary Figure 1A) and
decreased HCV propagation in genotype 2a HCVcc-
producing cells (Supplementary Figure 1C). NA255 is a
selective inhibitor of SPT that inhibits HCV replication by
suppressing the biosynthesis of sphingolipids that are
required for HCV replication in replicon cells.12 NA808
also inhibited the de novo synthesis of sphingolipids
(Supplementary Figure 1B). According to the resulting
Lineweaver-Burk plot of SPT inhibition in a replicon cell
lysate, NA808 exhibited a noncompetitive inhibition
pattern (Figure 1B). These ﬁndings suggest that NA808
inhibits HCV replication activities through the prevention
of sphingolipid biosynthesis by a noncompetitive inhibi-
tion mechanism of SPT.NA808 Shows a High Barrier to Resistance
In Vitro
To evaluate the potential development of resistance
to NA808, replicon cells (R6 FLR-N) were cultured in the
presence of both G418 and NA808 at a concentration of 4
to 6 times the IC50 for 14 passages. Obvious changes in
drug sensitivities to NA808 were not observed in these
continuously treated replicon cells (Figure 2A), and the
IC50 values were 18.9 nM (no treatment), 14.3 nM (treat-
ment with 4 times the IC50), and 19.8 nM (treatment with
6 times the IC50). In contrast, there was a 5- to 17-fold
increase of the IC50 values for telaprevir, an NS3/4 serine
protease inhibitor, in replicon cells treated with 4 to 6
times the IC50 of telaprevir for the same duration
(Table 1). The coding sequences of NS3 to NS5B from
the replicon system after 14 passages with telaprevir or
NA808 were determined by using deep sequencing. The
sequences obtained at the 14th passage with telaprevir
contained 3 known protease inhibitor resistance muta-
tions (V36A, T54V, and A156T)16 and NS5 region
(Q181H, P223S, and S417P) (Table 2), suggesting that the
increase in IC50 with telaprevir was accompanied by a shift
in viral sequence. In contrast, no signiﬁcant mutations
were found in the 14th passage with NA808. Continuously
treated replicon cells developed resistance to telaprevir,
but not to NA808.Anti-HCV Activities of NA808 in Chimeric
Mice With Humanized Liver Infected With
HCV
To evaluate the anti-HCV effect of NA808 in vivo,
we used chimeric mice with humanized liver infected with
HCV genotype 1a (HCG9) or 1b (HCR6). The chimeric
mice with humanized liver were immunodeﬁcient trans-
genic uPA/severe combined immunodeﬁcient mice with
reconstituted human liver; this mouse model supports
long-term HCV infections at clinically relevant titers.
We administered NA808 via intravenous injection ac-
cording to the schedule shown in Supplementary Table 1. In
mice infected with HCV genotype 1a, NA808 (5 mg/kg/d)
led to a rapid decrease in serumHCV-RNA (approximately a
Figure 1. Characteristics of
NA808. (A) Chemical structures
of the compounds used in this
study. (B) Scheme of de novo
sphingolipid biosynthesis and
Lineweaver-Burk plot of SPT
assay results. Crude extract of
FLR3-1 cells was incubated
with L-[14C]serine in the pres-
ence of NA808. After incuba-
tion at 37C, the extracts were
spotted on TLC plates and
chromatographed. 3-Keto-
dihydrosphingosine (3-KDS)
generated from a bacterial SPT
reaction is shown as a positive
control marker.
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in serum HCV-RNA occurred in mice infected with HCV
genotype 1b that were treated with NA808 (5 mg/kg/d)
(Figure 2D). NA808 also reduced hepatic HCV-RNA at the
end of the treatment period in a dose-dependent manner
(Figure 2C and E). These results indicate that NA808 has a
robust antiviral effect in chimericmicewith humanized liver
infected with HCV genotype 1a or 1b. The most effective
dose was 5 mg/kg/d in both genotype 1a and genotype
1binfected mice; therefore, we used this dose for further
experiments. To address whether NA808 had antiviral ac-
tivity across HCV genotypes, chimeric mice infected with
various strains of HCVwere treated with 5mg/kg of NA808
for 14 days, and then the HCV-RNA levels in the sera were
evaluated. Inoculation with several HCV strains, HCG9(genotype 1a), HCR6 (1b), HCR24 (2a), HCV-TYMM (3a),
andHCVgenotype4a/KM (4a), resulted in HCV titers in the
sera of mice of approximately 108 (HCG9 and HCV-
TYMM) and 107 (HCR6, HCR24 and HCVgenotype4a/
KM) copies/mL, respectively (Supplementary Figure 2, and
as described previously17). At 14 days after administration,
NA808 treatment resulted in approximately 1- to 3-log re-
ductions of serum HCV-RNA in each genotype-infected
group (Figure 2F). Human serum albumin levels were not
changed during the administration period (data not
shown), suggesting that the anti-HCV activity of NA808
against several genotypes occurred without any overt
toxicity. NA808 was effective and well tolerated in chimeric
mice with humanized liver infected with several genotypes
of HCV.
Table 1
Dru
NA808 (
Telaprev
Data are
Figure 2. Drug-resistance pro-
ﬁle and antiviral effects of
NA808 in various HCV geno-
types. (A) Activities on replicon
cells cultured with NA808.
Drug-resistant HCV replicons
were selected in the presence
of G418 and NA808 at a con-
centration of 4 to 6 times the
IC50. Changes in drug sensitivity
were examined after the 14th
passage. (B, D) Time course of
serum HCV-RNA levels in
chimeric mice infected with
HCV genotype 1a (B) or geno-
type 1b (D) treated with vehicle
or several doses of NA808
(closed circles: 5 mg/kg/d;
open circles: 3 mg/kg/d; closed
triangles: 1.5 mg/kg/d; open
triangles: vehicle). (C, E) HCV-
RNA levels in the livers of
chimeric mice infected with
HCV genotype 1a (C) or geno-
type 1b (E) at the end of
treatment. Error bars ¼ SD
(*P < .05). (F) Time course of
serum HCV-RNA levels in the
sera of genotype 1a (closed
circles), 1b (open circles),
2a (closed triangles), 3a (open
triangle), and 4a (closed
squares) after intravenous
administration of 5 mg/kg/d
NA808. Error bars ¼ SD.
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Chimeric Mice With Humanized Liver
Full-genome sequence analysis of HCV in the
humanized-liver mouse model after 14 days of NA808
administration was performed. The viral RNAwas extracted
from liver tissues of humanized-liver mice, ampliﬁed
by using the primer sets shown in Supplementary Table 3. Changes in Drug Sensitivities of HCV Replicon Cells
After the 14th Passage in the Presence of NA808 or
Telaprevir
g No treatment IC504 IC506
nM) 18.9  2.82 14.3  5.52 19.8  7.86
ir (mM) 0.39  0.022 2.14  0.019 6.48  1.30
indicated as mean  SD.and sequenced with the Roche/454 GS Junior sequencer
by using titanium chemistry. We obtained 43,911 and
68,272 sequence reads for HCV genomes from untreated
mice and from NA808-treated mice, respectively. The
sequences were determined by comparing with the
HCG9 reference sequence (GenBank accession number
AB520610). As a result, the viral sequences from NA808-
treated mice were identical to those from untreated mice.Synergistic Effects of NA808 With PEG-IFN or
DAAs in Chimeric Mice Infected With HCV
The in vivo synergistic effects of NA808 combined
with PEG-IFN on HCV replication were investigated by
using chimeric mice with humanized liver infected with
HCV genotypes 1a, 2a, and 4a. NA808 was administered
Table 2. Summary of Mutation Frequencies Detected by Using
Deep Sequencing for NA808- or Telaprevir-Treated
Replicon Cells
Drug Treatment Mutation Region Frequency (%)
Telaprevir IC506, 14 passages V36A NS3 18.1
T54V NS3 26.9
A156T NS3 12.9
Q181H NS5A 25.2
P223S NS5A 23.3
S417P NS5A 15.8
NA808 IC506, 14 passages Not detected
Nucleotide sequences based on deep sequencing of NS3 to NS5B region
from NA808- or telaprevir-treated replicon cells are compared with un-
treated controls, and amino acid mutations are shown.
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PEG-IFN for 14 days. In mice infected with HCV genotype
1a, the combination therapy of NA808 with PEG-IFN led
to a rapid decrease in serum HCV-RNA of about 4-log
within 10 days (Figure 3A), and monotherapy with
NA808 and PEG-IFN achieved about a 2-log and 1-log
decrease, respectively (Figure 4A). The levels of serum
HCV-RNA were also signiﬁcantly reduced in genotype 2a-
and 4ainfected chimeric mice that received the combi-
nation treatment (Figure 3A). Although sensitivities to the
combination treatment varied according to HCV genotype
(1a, 2a, or 4a), the serum HCV-RNA level eventually fell
below the level of detection in all mice treated with the
combination of NA808 and PEG-IFN (Figure 3A); this
result was consistent with the signiﬁcant reductions in
hepatic HCV-RNA levels at day 14 (Figure 3B).
To determine if NA808 has a synergic effect with
DAAs, we examined combination treatment with NS5B
nucleoside inhibitor, RO-9187,13 NS5B polymerase non-
nucleoside inhibitor, HCV-796, or NS3/4A protease in-
hibitor, telaprevir, in HCV genotype 1a- or 1b-infected
chimeric mice. Oral administration of once-daily 1000
mg/kg RO-9187, 100 mg/kg HCV-796, or 400 mg/kg
telaprevir had only very limited effects or no apparentFigure 3. Antiviral effect of combination treatment of NA808 with PEG-IF
levels in chimeric mice infected with genotype 1a, 2a, or 4a and treated
(30 mg/kg/twice weekly, subcutaneously). HCV-RNA levels one day befo
liver 14 days after the initiation of combination therapy with NA808 and PEeffects on serum HCV-RNA levels during the 14 days of
treatment (Figure 4B, C, and D). However, the combi-
nation therapy of NA808 with RO-9187, HCV-796, or
telaprevir led to decreases in serum HCV-RNA levels of
about 2.6-log, 3.5-log, and 2.5-log, respectively, within
14 days (Figure 4B, C, and D); these reductions were all
in excess of viral load reductions achieved by treatment
with NA808 (5 mg/kg) alone. After 28 days of combi-
nation treatment with NA808 and telaprevir, serum
HCV-RNA levels were reduced by 104-fold (data not
shown). These data suggest that NA808 has synergistic
antiviral effects with HCV enzyme-targeted drugs in vivo,
regardless of the targeted enzyme. The combination
therapy of NA808 with telaprevir and HCV-796 resulted
in up to a 4.7-log reduction of serum HCV-RNA within
14 days (Figure 4D). At the end of the treatment, hepatic
HCV-RNA levels were also reduced, correlating with the
reduction of serum HCV-RNA (Figure 4E).N on HC
with a c
re admin
G-IFN. EPharmacokinetics Data of Chimeric Mice
Treated With NA808
We measured the plasma concentration of NA808
in humanized-liver mice at 24 hours after 14 days of treat-
ment. The plasma concentrations of NA808 at trough level
were 0.510  0.517 nmol/L (1.5 mg/kg), 0.446  0.163
nmol/L (3 mg/kg), and 1.44  1.07 nmol/L (5 mg/kg),
respectively (Table 3). Obvious toxicological ﬁndings in gen-
eral conditions were not observed at any doses. We selected
1.4 nmol/L as an effective trough level of NA808 in vivo.Discussion
The current treatment regimen for HCV infection
is combination therapy with PEG-IFN and RBV; however,
this combination therapy has limited efﬁcacy and is not
well tolerated in many patients due to its systemic side-
effect proﬁle.3,4 Although the HCV NS3/4A protease in-
hibitors telaprevir and SCH503034 (boceprevir) have been
recently approved for the treatment of chronic HCVV-infected chimeric mice. (A) Time course of serum HCV-RNA
ombination of NA808 (5 mg/kg/d, intravenously) and PEG-IFN
istration are shown in black bars. (B) HCV-RNA levels in the
rror bars ¼ SD. *P < .05; **P < .01.
Figure 4. Combination treat-
ment of NA808 with PEG-IFN or
direct-acting antiviral agents
exhibits robust anti-HCV activity
in chimeric mice with human-
ized liver. (AD) Median change
from baseline of serum HCV-
RNA over the 14-day mono-
therapy or combination therapy
of NA808 (5 mg/kg/d, intrave-
nously) with PEG-IFN (A: 30 mg/
kg/twice weekly, subcutane-
ously), RO-9187 (B: 1000 mg/
kg/d, orally), HCV-796 (C: 100
mg/kg/d, orally), or telaprevir
(400 mg/kg/d, orally) and/or
HCV-796 (D). (E) HCV-RNA
levels in livers of HCG9-
infected chimeric mice at the
end of each treatment. Error
bars ¼ SD. (*P < .05).
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current standard of care.5 Therefore, the ultimate goal of
developing a therapy for chronic hepatitis C is likely to
combine HCV enzyme-targeting agents without the use of
IFN or RBV. Currently, combination therapies of DAAs,
such as NS3/4 serine protease inhibitors, NS5B RNA-Table 3. Plasma Concentration of NA808 in Humanized-Liver
Mice at 24 Hours After Last Dosing
Dose Concentration (nmol/L)a
1.5 mg/kg 0.510  0.517
3.0 mg/kg 0.446  0.163
5.0 mg/kg 1.44  1.07
aData are indicated as mean  SD.dependent RNA polymerase inhibitors, and NS5A in-
hibitors, are being tested in clinical trials; however, the
emergence of resistance mutations limits the efﬁcacy of
these therapies.8,9 In addition, the antiviral activities of
DAAs are reduced for certain HCV genotypes.11 Additional
antiviral agents with high barriers to resistance and potent
antiviral activities against a wide variety of HCV genotypes
are necessary to establish robust and effective antiviral
combination therapies without the use of IFN or RBV.
The infection and replication process of HCV can use not
only NS3, NS4, and NS5 proteins, but also several known
and unknown host protein factors. Drugs that target host
protein factors could provide therapies against HCV with
a high barrier to resistance.
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ERIn the present study, we evaluated the anti-HCV activity
of NA808, a novel host SPT inhibitor in vitro and in vivo.
The inhibitory activity of NA808 is attributed to the in-
hibition of the cellular enzyme SPT, which is necessary for
viral replication. The mode of action of NA255, a lead
compound of NA808, is the disruption of the scaffold
where the HCV replication complex forms on host cellular
lipid rafts.12 NA808 potently inhibits the de novo
biosynthesis of cellular sphingolipids, such as ceramide
and sphingomyelin, in a dose-dependent manner
(Supplementary Figure 1B). We have recently reported that
NA808 inﬂuences sphingolipid metabolism in host cells
along with its biosynthesis and that sphingomyelin, a
type of sphingolipid, plays a multifaceted role in the HCV
life cycle.18 Additionally, the alteration of sphingolipid
metabolism contributes to virion maturation and infec-
tivity in the JFH-1 culture system.19 These results suggest
that NA808 affects many phases of the life cycle, including
entry, replication, and maturation. It seems that these
diverse working points in the HCV life cycle along with the
differentials of the target site could be a reason for the
enhanced anti-HCV activity of combination treatment
with NA808 and DAAs.
Myriocin, another SPT inhibitor, strongly reduces the
expression of hemagglutinin and neuraminidase of inﬂu-
enza virus glycoproteins and inhibits the release of virus
particles from infected cells.20 The mechanism of inhibi-
tion involves the sphingomyelin biosynthetic pathway,
which plays a critical role in the generation of inﬂuenza
virus particles. In another report, Miller et al found that
ebola virus particles strongly associate with the
sphingomyelin-rich regions of the cell membrane and that
depletion of sphingomyelin reduces ebola virus infec-
tion.21 Lipid rafts, sphingolipid-enriched membrane
microdomains, are involved in the entry, assembly, and
budding of various types of viruses other than HCV,
including several viruses with a serious public health
concern. SPT inhibitors, such as NA808, have the potential
to affect the life cycle of the other families of viruses and
provide therapeutic options for these difﬁcult-to-treat viral
infections via the inhibition of sphingolipid biosynthesis
and modiﬁcation of its metabolism, as described here.
Based on the mechanism of action, NA808 could be
anticipated to have antiviral activity against a wide variety
of HCV genotypes as compared with DAAs. To estimate
the effects of NA808 in DAA combination therapy without
the use of IFN or RBV, a combinatorial treatment with
NA808 and NS5B polymerase inhibitors and/or NS3/4A
protease inhibitors was evaluated in chimeric mice with
humanized liver infected with HCV. Both non-nucleoside
inhibitors and nucleoside inhibitors of NS5B are currently
being tested in clinical trials, and the most advanced
protease inhibitors, such as telaprevir, are linear com-
pounds and are currently on the market; several macro-
cyclic compounds are being tested in clinical trials.11,2225
Monotherapy with the non-nucleoside polymerase inhib-
itor, HCV-796, showed less than a 0.5 log10 reduction of
serum HCV RNA levels, while a combined treatment withNA808 reduced the HCV titer by 1000-fold from the initial
serum levels. This effect was higher than the effect of
NA808 alone and higher than the sum of NA808 and
HCV-796 monotherapy effects, suggesting synergistic
antiviral efﬁcacy. A similar effect was observed by combi-
nation of NA808 with nucleoside polymerase inhibitor,
RO-9187, as shown in Figure 4B. The maximum re-
ductions in HCV RNA are mediated by triple combina-
torial treatment and the signiﬁcant in vivo anti-HCV
activity with combination treatment is also observed
when NA808 is combined with PEG-IFN. These observa-
tions suggest that NA808 may have synergistic antiviral
activity with various classes of anti-HCV agents, regardless
of their inhibition mechanism, due to the unique host
enzyme-targeted mechanism of action. In addition, NA808
could be expected to show a higher barrier to the devel-
opment of resistant clones. Deep-sequencing analysis
showed no evidence for the development of NA808 resis-
tance after 14 passages in HCV replicon cells, while
telaprevir treatment resulted in the selection of known
protease resistance mutations (V36A, T54V, and A156T)
(Table 2). The full-genome sequence of HCV obtained at
day 14 from HCV-infected humanized-liver mice treated
with NA808 for 14 days also showed no evidence for the
selection of resistance mutations, consistent with the viral
load kinetics (Figure 2B).
Host enzyme inhibition might be associated with
mechanism-related toxicities or side effects. Althoughmore
thorough analyses of toxicity with NA808 are warranted,
NA808 did not affect host cell viability in vitro under the
assay conditions used (Supplementary Figure 1A), and it
was well-tolerated in vivo at the efﬁcacious dose used. The
effective plasma concentration of NA808 at trough level
was approximately 1.4 nmol/L (Table 3), around 100 times
lower than rats that received 40 mg/kg NA808 at 24 hours
after injection (data not shown). No NA808-related
changes, including abnormalities of general conditions,
body weight decreases, and macroscopic or microscopic
changes were observed at this high dose in rats. Homozy-
gous knockout mice for sptlc1 and sptlc2, subunits of SPT,
were embryonic lethal, and heterozygous mice showed no
phenotype.26 Mice with conditional sptlc2 knockout
showed necrotic lesions in gastrointestinal cells.27 The
highly selective distribution of NA808 to the liver can
contribute to limit potential systemic toxicities associated
with SPT inhibition by NA808.28
In conclusion, NA808 mediates potent anti-HCV ac-
tivities in a variety of genotypes with an apparent high
barrier to resistance. Synergistic effects with PEG-IFN,
HCV protease, and/or polymerase inhibitors are ob-
served in chimeric mice with humanized liver infected
with HCV. These ﬁndings suggest that NA808 has po-
tential as a novel host-targeted drug in the treatment of
HCV infection. NA808 is considered a promising
candidate for DAA combination treatment without the
use of IFN or RBV to prevent the development of drug
resistance and effectively inhibit a wide spectrum of
HCV genotypes.
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